Advancing Early-Stage TCR Targeted Treg Cell Therapy Programs for Autoimmune Diseases with Substantial Unmet Need

Time: 12:00 pm
day: Conference Day One


  • Developing TCR-Treg therapies for tissue-specific autoimmune diseases including multiple sclerosis and type 1 diabetes
  • Stopping immune-mediated destruction, restore homeostasis, and promote repair in effected tissues
  • Advancing our programs with plans to initiate its first clinical study in 2024